Portfolio
Pharmion Corp. was a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients.
Pharmion Corp. had a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent.
In 2003 Pharmion Corp. successfully completed an Initial Public Offering on NASDAQ and in 2007 was acquired for total considerations of $2.9 billion by Celgene Corp. (NASDAQ:CELG).
Status: Realised
Investment
NeoMed identified Pharmion Corp. as an attractive investment opportunity through personal contacts and network in the industry.
In 2001 NeoMed was invited to participate in a strong US-led syndication.
NeoMed held regular meetings with the company CEO and European marketing Vice President.
NeoMed sold its shares on NASDAQ in 2004.